Advances in Delivery Systems for Antidiabetic Drugs and Beyond Glycaemic Control

Dear Colleagues,

Diabetes is a serious endocrinological disease that affects many body organs. Early diagnosis and suitable treatment are highly recommended to prevent the sequelae of this metabolic disorder. Researchers over decades have attempted to optimise the pharmacological benefits of different therapeutics, peptides and herbal isolates to either reverse the hyperglycaemic state or to maintain normoglycaemia over long periods of time. Such scrutinised physiological control could only be achieved through advanced pharmaceutical delivery systems and new platforms in the therapeutic delivery of antidiabetic agents. This Special Issue is aiming to highlight the state-of-the art drug delivery systems, platforms and devices for antidiabetic therapeutics. This Special Issue covers the application of pharmaceutical technologies employed in the advancements of the therapeutic delivery of insulin, biguanides, sulfonylureas, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 analogues, sodium-glucose co-transporter 2 inhibitors, thiazolidinediones and herbal isolates.

 This issue covers but is not limited to the following:

• Novel approaches in medical devices and diagnostics of diabetes.
• Novel pharmaceutical scaffolds for targeted drug delivery of anti-diabetics.
• Novel implantable devices, inserts and transdermal patches of antidiabetics.
• Novel injectable, rectal, sublingual and other pharmaceutical routes that bypass hepatic metabolism of antidiabetics.
• Novel micro/ nanoscale biomaterials and biodegradable polymers employed in antidiabetic delivery.
• New formulation approaches of antidiabetics such as pH-responsive systems and 3D printing.
• New functionalised polymers/biopolymers, self-assembly and electrospinning approaches of anti-diabetics.
• Novel pharmaceutical coatings for site specific anti-diabetic release.
• The use of AI in pharmaceutical design and optimisation of the delivery and the pharmacokinetics of anti-diabetic agents.
• Pharmaceutical technologies for optimised pharmacokinetics of anti-diabetic agents.
• New therapeutic applications and novel findings of old antidiabetic agents beyond the glycaemic effects.

The issue welcomes original research papers, mini-review articles, short communications, expert opinions, and critical reviews.

Dr. Ahmed Gedawy
Prof. Dr. Crispin R. Dass
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.